The refractive surgeon's secret to enhanced success

Article

In this article Dr Kanellopoulos shares his opinions on AS-OCT in his practice, highlighting the clinical and diagnostic advantages he has experienced using the imaging device.

The beauty of recent developments in the AS-OCT that my colleagues and I have chosen for our practice (RTVue, Optovue Inc., Fremont, California, USA) is that it allows for an extremely simple examination that does not require a highly skilled examiner. It is user-friendly and, like other diagnostic devices we choose for our office, has point-and-shoot simplicity with high reproducibility. Optovue has recently launched a new, highspeed OCT, Avanti, and in my opinion, the widefield imaging and scan speed available on that device is unparalleled, and the large screen size allows a clinician to detect pathology better than a limited scan size.

The clinical science of a spectral domain OCT epithelial imaging comes into play when making surgical decisions not only postoperatively but also preoperatively. For example, it is commonly useful when a patient needs to be further evaluated for suspicious topography. Dry eye, blepharitis, contact lens use and even overmedication with drops in the office, may interfere with the intact epithelial distribution.

An epithelial map may be the 'missing' part of the puzzle when making decisions for refractive surgery. If a patient's anatomy is normal, then we can rely more on other imaging devices that provide the basics, such as the curvature and the power of the different parts of the cornea. If the epithelium is abnormal, then one has to take that into account, first, because an abnormal epithelium can interfere with Scheimpflug imaging, meaning Scheimpflug imaging may become significantly biased by such changes. Additionally, if the epithelium is abnormal, the better way to document it is with an epithelial map.

It has been to our surprise that many mishaps in refractive surgery and IOL lens calculation in cataract surgery were related to our inability, up until now, to have a reproducible, easily attainable epithelial map in patients.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Marjorie Rah, OD, PhD, FAAO
Dr Richard Lindstrom, Chairman of Surface Ophthalmics and founder of Minnesota Eye Consultants, speaks about ASCRS
Josefina Botta, MD, MSc, at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.